Senior insider sale
TAYSHA GENE THERAPIES, INC. — senior position signals high conviction
$2.69M
570.17K shares
What this filing means
NAGENDRAN SUKUMAR plans to sell 570.17K shares of TAYSHA GENE THERAPIES, INC. valued at approximately $2.69M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 1/12/2026ACC: 0001974158-26-000011
Director
Since Sep 2020
570.17K
Shares to sell
$2.69M
Approx. market value
200K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months2
Vested Stock Option Grant
N/A
1/2/2024
88.68KVested Stock Option Grant
N/A
5/31/2023
111.32KTotal acquired200K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
1/2/2024 | Vested Stock Option Grant N/A | 88.68K | — |
5/31/2023 | Vested Stock Option Grant N/A | 111.32K | — |
| Total | 200K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
260.05K
Market value
$1.17M
12/1/2025
—Completed
Units to sell
110.13K
Market value
$522.8K
11/28/2025
Planned — Approximate Date
NasdaqPlanned
Units to sell
200K
Market value
$996.0K
1/12/2026
Total
Units
570.17K
Value
$2.69M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
12/1/2025 | 260.05K | $1.17M | — | Completed |
11/28/2025 | 110.13K | $522.8K | — | Completed |
| Planned — Approximate Date | ||||
1/12/2026 | 200K | $996.0K | Nasdaq | Planned |
| Total | 570.17K | $2.69M | ||